Prof Andrew Kneebone
/content/dam/genesiscare/headshots/au-doctor-headshots/AU_Oncology_Headshot_GA_Prof Andrew Kneebone.jpg

Prof. Andrew Kneebone

Prof. Andrew Kneebone
MBBS, FRANZCR, Radiation Oncologist

Languages spoken




Mater Hospital, Sydney (Oncology)
Mater Hospital, Sydney (Oncology)
-33.83166139694626, 151.20156682718073

Clinical interests in gastrointestinal (GI), prostate, and genitourinary cancers.

Andrew is a radiation oncologist, with extensive clinical experience offering treatment for gastrointestinal (GI) and genitourinary cancers.

Andrew is a passionate and energetic clinician who’s committed to building caring and honest relationships with his patients.

His clinical experience, understanding and dedication are valuable for patients, knowing that Andrew aims to deliver high-quality, evidence-based patient care.

Andrew has been recognised by the Royal Australian and New Zealand College of Radiologists (RANZCR) with the Denise Lonergan award, for his commitment, participation, and leadership in training and education for radiation oncology.

Clinical and research interests

Andrew is a committed teacher for medical students and junior doctors. He lectures at the University of Sydney and has been the Director of Registrar Training for more than 20 years.

Andrew is an active researcher, with more than 140 peer reviewed publications. He is the chief investigator in several important NHMRC funded national clinical trials in prostate and pancreatic cancer.

Professional memberships

Andrew has been an invited speaker at more than 90 conferences or meetings, and has served on numerous state and national committees on cancer management.

Andrew has been the chair of both the national Radiation Oncology Genitourinary executive (FROGG) and the Radiation Oncology Executive for the Australian Gastro-Intestinal Trials Group (AGITG). He’s also served on the National Board of the Prostate Cancer Foundation of Australia and has been made an Honorary Life member.


Andrew has developed published national guidelines for prostate cancer, bladder cancer, anal cancer, and pancreatic cancer.